Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Martin Gutierrez, MD
Hackensack Meridian Health
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Lombardi Comprehensive Cancer Center, Georgetown University
Washington D.C., District of Columbia, United States
Not, yet, recruiting - John Theurer Cancer Center, Hackensack Meridian Health
Hackensack, New Jersey, United States
Recruiting - Jersey Shore University Medical Center
Neptune City, New Jersey, United States
Not, yet, recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 29 Sept 2023
- Primary completion
- 28 Apr 2027
- Completion
- 28 Apr 2027
- Last update posted
- 18 Feb 2026
- Registered enrollment
- 108
- Registry id
- NCT05715229
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.